John McHutchison AO, MD is a Board Member at Tune Therapeutics, and former President and CEO of Assembly Biosciences.
At Assembly, he led the company’s progress in the anti-viral space before transitioning to the board of directors and chairing the Science and Technology Committee. Prior to Assembly, he served as Chief Scientific Officer and Head of Research and Development at Gilead Sciences, where he led the development of a broad range of liver-directed therapies, including the curative HCV antiviral regimens and investigational therapies against nonalcoholic steatohepatitis (NASH). John was also instrumental in Gilead’s transformative acquisition of Kite Therapeutics, and its subsequent leadership position in the CAR T cell therapy field.
Dr. McHutchison received his degrees in medicine and surgery from the University of Melbourne in Australia, and completed a post-doctoral fellowship in Liver Diseases at the University of Southern California. He is a member of the Royal Australasian College of Physicians, and was appointed an Officer of the Order of Australia (AO) in 2018.